Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Our new book is a comprehensive look at a vital part of medicines development and regulatory affairs. Grab your copy today!
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
| 31 March 2014 | By Louise Zornoza,
Drug manufacturers must now provide a year's notice to Brazil's national regulator, Anvisa, prior to withdrawing a drug from the market if that withdrawal might lead to a shortage of the drug.
The objective of the new mandate, approved on 25 March 2014, is to reduce the potential impact of any drug shortage on the patient population for which the drug is indicated.
The 12-month notice mandate also covers situations where the intent is merely to reduce the level of production or importation of a drug, rather than total marketing withdrawal. If the withdrawal or production reduction would not pose a risk of a shortage, the mandatory notice can be made six months ahead rather than twelve. There is a 72-hour notice requirement if sudden previously unforeseen circumstances could lead to a drug shortage.
Read all Breaking News from RegLink
Tags: Drug Shortage, Drug Shortages, brazil